share_log

Insiders Were the Key Beneficiaries as Tuoxin Pharmaceutical Group Co.,Ltd.'s (SZSE:301089) Market Cap Rises to CN¥4.4b

ツォシン医薬品グループの時価総額が44億元に上昇した中で、内部者が主な恩恵を受けました(SZSE:301089)。

Simply Wall St ·  08/16 20:07

Key Insights

  • Insiders appear to have a vested interest in Tuoxin Pharmaceutical GroupLtd's growth, as seen by their sizeable ownership
  • 52% of the business is held by the top 5 shareholders
  • Using data from company's past performance alongside ownership research, one can better assess the future performance of a company

If you want to know who really controls Tuoxin Pharmaceutical Group Co.,Ltd. (SZSE:301089), then you'll have to look at the makeup of its share registry. With 55% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

As a result, insiders scored the highest last week as the company hit CN¥4.4b market cap following a 11% gain in the stock.

In the chart below, we zoom in on the different ownership groups of Tuoxin Pharmaceutical GroupLtd.

big
SZSE:301089 Ownership Breakdown August 17th 2024

What Does The Institutional Ownership Tell Us About Tuoxin Pharmaceutical GroupLtd?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Since institutions own only a small portion of Tuoxin Pharmaceutical GroupLtd, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. So if the company itself can improve over time, we may well see more institutional buyers in the future. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.

big
SZSE:301089 Earnings and Revenue Growth August 17th 2024

We note that hedge funds don't have a meaningful investment in Tuoxin Pharmaceutical GroupLtd. Xining Yang is currently the largest shareholder, with 27% of shares outstanding. In comparison, the second and third largest shareholders hold about 14% and 4.2% of the stock. Yuying Cai, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.

To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.

Insider Ownership Of Tuoxin Pharmaceutical GroupLtd

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

It seems that insiders own more than half the Tuoxin Pharmaceutical Group Co.,Ltd. stock. This gives them a lot of power. That means they own CN¥2.4b worth of shares in the CN¥4.4b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

General Public Ownership

The general public, who are usually individual investors, hold a 41% stake in Tuoxin Pharmaceutical GroupLtd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Tuoxin Pharmaceutical GroupLtd better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Tuoxin Pharmaceutical GroupLtd .

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする